martes, 22 de mayo de 2018

A Second CD4-binding Region of HIV-1 gp120 Critical for Viral Infectivity: New Methods for Treatment and Vaccine Development | Office of Technology Transfer, NIH

A Second CD4-binding Region of HIV-1 gp120 Critical for Viral Infectivity: New Methods for Treatment and Vaccine Development | Office of Technology Transfer, NIH





 Vaccine and Drug Development Opportunity:
New Methods for Prevention and Treatment of HIV Infection
CD4 bound HIV1

Top view of the cryo-EM structure of a single CD4-bound HIV-1 Env trimer showing the quaternary interaction of CD4 (yellow) with neighboring gp120 protomers; gp41 was removed for clarity. Inset shows a close-up representation of CD4 residues (highlighted by sticks representation and color) at the interface with the second CD4-binding site (CD4-BS2) in gp120 (D63, negatively charged; K21 and K22, positively charged). Credit: NIAID





NIAID scientists have identified a portion of the HIV envelope protein that is critically involved in HIV entry and infection. If stabilized and purified, this portion of the HIV envelope protein may be used to immunize and protect individuals against HIV infection. This discovery may also lead to the development of new HIV therapies that inhibit HIV entry into uninfected cells. Read more about this exciting collaboration/licensing opportunity athttps://www.ott.nih.gov/technology/e-230-2015

No hay comentarios:

Publicar un comentario